Phytochemicals in Alzheimer disease: The development of clinical trials

被引:5
|
作者
Quinn, J
Kaye, J
Montine, T
Stackman, R
机构
[1] Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA
[3] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
关键词
Alzheimer disease; antioxidants; oxidative stress; polyphenolics;
D O I
10.3109/138802090893531
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that. are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 50 条
  • [41] The search for meaning in preclinical Alzheimer disease clinical trials
    Han, S. Duke
    Shinotoh, Hitoshi
    NEUROLOGY, 2019, 93 (04) : 139 - 140
  • [42] Imaging endpoints for clinical trials in Alzheimer's disease
    Cash D.M.
    Rohrer J.D.
    Ryan N.S.
    Ourselin S.
    Fox N.C.
    Alzheimer's Research & Therapy, 6 (9)
  • [43] Iron Chelators and Alzheimer's Disease Clinical Trials
    Mandal, Pravat K.
    Maroon, Joseph C.
    Samkaria, Avantika
    Arora, Yashika
    Sharma, Shallu
    Pandey, Ashutosh
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 100 : S243 - S249
  • [44] Drug candidates in clinical trials for Alzheimer's disease
    Hung, Shih-Ya
    Fu, Wen-Mei
    JOURNAL OF BIOMEDICAL SCIENCE, 2017, 24
  • [45] Can clinical trials better address Alzheimer disease clinical management?
    Becker, R
    NEUROBIOLOGY OF AGING, 2004, 25 : S2 - S2
  • [46] Clinical Data Interchange Standards in Clinical Trials on Alzheimer?s Disease
    Na, Riyoung
    Bin Bae, Jong
    Jung, Sue Hyun
    Kim, Ki Woong
    PSYCHIATRY INVESTIGATION, 2022, 19 (10) : 814 - 823
  • [47] Development of a pool of items to assess activities of daily living in clinical trials for Alzheimer's disease
    Galasko, D
    Bennett, D
    Ernesto, C
    Thomas, R
    Sano, M
    NEUROLOGY, 1996, 46 (02) : 3075 - 3075
  • [48] Alzheimer's disease, estrogens, and clinical trials: A case study in drug development for complex disorders
    Howell, N
    Dykens, J
    Moos, WH
    DRUG DEVELOPMENT RESEARCH, 2005, 66 (02) : 53 - 77
  • [49] Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials
    Hung, Anna
    Schneider, Monika
    Lopez, Marianne Hamilton
    McClellan, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (07): : 888 - 900
  • [50] Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies
    Zhang, Jifa
    Zhang, Yinglu
    Wang, Jiaxing
    Xia, Yilin
    Zhang, Jiaxian
    Chen, Lei
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)